Abstract B059: Loss of Cullin-RING Ligase 5 mediates resistance to RAS inhibition in pancreatic cancer
How selective modulation of protein degradation governs adaptive resistance to RAS inhibition governs adaptive resistance to RAS inhibition and provide a framework for developing rational combination strategies to improve the durability of RAS-targeted therapies in PDAC is defined.